{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:46:03Z","timestamp":1776743163349,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2025.10.016","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T04:02:08Z","timestamp":1761364928000},"page":"232-243.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7167-4710","authenticated-orcid":false,"given":"Akhil","family":"Rajendra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-3680","authenticated-orcid":false,"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniket","family":"Bankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Agustina","family":"Perusini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Richard-Carpentier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Sibai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-9380","authenticated-orcid":false,"given":"Dawn","family":"Maze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.10.016_bib0001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2141.1999.01684.x","article-title":"A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial","volume":"107","author":"Wheatley","year":"1999","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.10.016_bib0002","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood-2002-02-0532","article-title":"Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 trial","volume":"101","author":"Kern","year":"2003","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2025.10.016_bib0003","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.016_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100806","article-title":"The complete story of less than complete responses: the evolution and application of acute myeloid leukemia clinical responses","volume":"48","author":"Shallis","year":"2021","journal-title":"Blood Rev"},{"issue":"12","key":"10.1016\/j.clml.2025.10.016_bib0005","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.10.016_bib0006","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.10.016_bib0007","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.2009.25.1066","article-title":"Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center study","volume":"28","author":"Walter","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.10.016_bib0008","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","article-title":"Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia","volume":"33","author":"Chen","year":"2015","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2025.10.016_bib0009","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.10.016_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2025.10.016_bib0011","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.10.016_bib0012","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2025.10.016_bib0013","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European Leukemia Net MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2025.10.016_bib0014","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2025.10.016_bib0015","first-page":"e44","article-title":"Clinical utility of next-generation sequencing in the management of myeloproliferative neoplasms: a single-center experience","volume":"2","author":"Alduaij","year":"2018","journal-title":"Hema Sphere"},{"issue":"6","key":"10.1016\/j.clml.2025.10.016_bib0016","doi-asserted-by":"crossref","first-page":"759","DOI":"10.5858\/arpa.2016-0547-RA","article-title":"Integration of technical, bioinformatic, and variant assessment approaches in the validation of a targeted next-generation sequencing panel for myeloid malignancies","volume":"141","author":"Thomas","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.clml.2025.10.016_bib0017","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ajcp\/aqab039","article-title":"The interpretation of sequence variants in myeloid neoplasms: an ACLPS critical review","volume":"156","author":"Hanbazazh","year":"2021","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.clml.2025.10.016_bib0018","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/bloodadvances.2023012127","article-title":"Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes","volume":"8","author":"Perusini","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2025.10.016_bib0019","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.leukres.2015.10.005","article-title":"Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.clml.2025.10.016_bib0020","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2025.10.016_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15099","article-title":"Clonal evolution in myelodysplastic syndromes","volume":"8","author":"da Silva-Coelho","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.clml.2025.10.016_bib0022","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/leu.2017.17","article-title":"The clonal origins of leukemic progression of myelodysplasia","volume":"31","author":"Kim","year":"2017","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.016_bib0023","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1182\/blood-2022-170069","article-title":"RAS pathway mutations are associated with progression after hypomethylating agent therapy in chronic myelomonocytic leukemia","volume":"140","author":"Montalban-Bravo","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.10.016_bib0024","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood-2015-11-679167","article-title":"Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure","volume":"128","author":"Mossner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.016_bib0025","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1182\/blood-2024-208602","article-title":"Cohesin complex gene mutated acute myeloid leukemia (AML) responds favorably to venetoclax based frontline therapy","volume":"144","author":"Senapati","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.10.016_bib0026","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clml.2025.10.016_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0094-3","article-title":"Impact of blood count recovery on outcomes of acute myeloid leukemia patients achieving morphologic leukemia-free state","volume":"8","author":"Cheng","year":"2018","journal-title":"Blood Cancer J"},{"issue":"31","key":"10.1016\/j.clml.2025.10.016_bib0028","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1200\/JCO.2015.62.0864","article-title":"Acute myeloid leukemia response measures other than complete remission","volume":"33","author":"Przepiorka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2025.10.016_bib0029","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2025.10.016_bib0030","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41409-021-01261-6","article-title":"Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation","volume":"56","author":"Percival","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2025.10.016_bib0031","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2023011219","article-title":"A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML","volume":"8","author":"Ravindran","year":"2024","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.clml.2025.10.016_bib0032","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.10.016_bib0033","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.bbmt.2015.03.022","article-title":"Hematologic recovery after pretransplant chemotherapy does not influence survival after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients","volume":"21","author":"Vu","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:18:14Z","timestamp":1776741494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265025042582"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}